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Abstract
Dendritic cells (DC) manipulate tissue homeostasis by recognizing dying cells and controlling immune functions. However,
the precise mechanisms by which DC recognize different types of dying cells and devise distinct immunologic
consequences remain largely obscure. Herein, we demonstrate that Milk-fat globule-EGF VIII (MFG-E8) is a critical mediator
controlling DC immunogenicity in inflammatory microenvironments. MFG-E8 restrains DC-mediated uptake and recognition
of necrotic cells. The MFG-E8-mediated suppression of necrotic cell uptake by DC resulted in the decreased proinflammatory
cytokines production and activated signal components such as STAT3 and A20, which are critical to maintain tolerogenic
properties of DC. Furthermore, the DC-derived MFG-E8 negatively regulates the cross-priming and effector functions of
antigen-specific T cells upon recognition of necrotic cells. MFG-E8 deficiency enhances an ability of necrotic cell-primed DC
to stimulate antitumor immune responses against established tumors. Our findings define what we believe to a novel
mechanism whereby MFG-E8 regulates the immunogenicity of DC by modulating the modes of recognition of dying cells.
Manipulating MFG-E8 levels in DC may serve as a useful strategy for controlling inflammatory microenvironments caused by
various pathological conditions including cancer and autoimmunity.
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Introduction
Dendritic cells (DC) serve as sentinels linking between innate
and adaptive responses [1]. In addition to responses triggered via
innate immune sensing such as pathogen- and/or endogenous
danger-associated signals, the ability of DCs to activate adaptive
immune responses relies mainly on the processing and presenta-
tion of immunogenic antigens [2,3]. This assumption implies that
the mode of presentation and recognition of immunogenic
antigens on DC may have a determinant role in the initiation
and promotion of antigen-specific immune responses.
Milk-fat globule EGF-8 (MFG–E8) is a phosphatidylserine-
binding protein secreted by subsets of myeloid cells that signals
through engaging avb3–5 integrins. The major functions of MFG-
E8 are to regulate immune homeostasis through the phagocytosis
of apoptotic cells [4–6]. We previously demonstrated that systemic
targeting of MFG-E8 enhances antitumor immune responses by
augmenting cross-presentation of immunogenic antigens [7–9].
However, how MFG-E8 directly influences the recognition
systems of dying cells by DC remains largely unknown. Here we
demonstrate that MFG-E8-dependent recognition of apoptotic
cells facilitates the tolerogenic activity of dendritic cells, whereas
necrotic cell-mediated inflammation and cross-priming of antigen-
specific cells is triggered by MFG-E8-deficient DC in a RIP1
(Receptor-interacting serine-threonine kinase)-dependent manner.
Thus, we delineate the novel mechanisms by which DC regulate
the delicate balance between immunity and tolerance by fine-
tuning recognition of dying cells in an MFG-E8-dependent
manner.
Results
MFG-E8 maintains the tolerized phenotype of DC under
steady and inflammatory conditions
To investigate whether MFG-E8 has impacts on the activities
and immunogenicity of DC, MFG-E8
high immature DC (iDC)
were generated from the bone marrow cells of wild-type or MFG-
E8-deficient mice using GM-CSF. The iDC treated with an
inflammatory element such as CD40 ligand served as mature DC
(mDC), in which MFG-E8 levels were low [9]. In some cases, five
sequences of siRNA specific for the murine MFG-E8 gene, which
were validated for inhibition of murine MFG-E8 expression by
RT-PCR (Figure 1A), were introduced into the wild-type BMDC.
The cells were then treated with a CD40 ligand, and subjected to
phenotypic analysis. Unstimulated DC from wild-type mice
displayed an immature phenotype, comprising moderate levels
of MHC-II, CD83 and CD86. In contrast, MFG-E8-deficient iDC
or wild-type DC in which MFG-E8 gene was targeted by several
siRNAs exhibited elevated expression of the costimulatory
molecules CD86 and CD83 even in the absence of maturation-
inducing stimulus (Figure 1B and C). Stimulation of DC with
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39607
5CD40L or TNF-a induced upregulation of the maturation
markers CD83 and CD86, but not MHC-II at greater levels in
MFG-E8-KO than wild-type DC (Figure 1B, C and data not
shown). Together, these results suggest that MFG-E8 potentially
restrains the co-stimulatory capabilities of DC under steady and
inflammatory conditions.
MFG-E8 deficiency facilitates the uptake of necrotic cells
MFG-E8 promotes the uptake and processing of apoptotic cells
by DC, which may promote Foxp3
+ regulatory T cell differen-
tiation and suppress antigen-specific adaptive immunity [6,9].
Several lines of evidences have revealed the impact of apoptotic
cell engulfment in maintaining immune homeostasis and prevent-
ing excess inflammation [5,10]. On the other hand, necrotic cells
contribute to the formation of immunogenic microenvironments
through activation of various proinflammatory mediators and
danger-associated signals [11,12]. However, whether MFG-E8-
mediated recognition of necrotic cells has any impact on the
effector activities of DC remains unknown. Therefore, we first
evaluated the phagocytosis of dying tumor cells by MFG-E8-KO
and wild-type DC. In this setting, we defined apoptotic cells as
annexin-V
+ PI
2 cells induced by the chemotherapeutic agent
cisplatin (CDDP) or c-irradiation (IR). Necrotic cells were induced
by CDDP or c-irradiation plus the caspase inhibitor zVAD-fms,
and were confirmed as Annexin-V
2 PI
+ populations by flow
cytometry (Figure S1 and data not shown). The PKH26-labeled
apoptotic or necrotic cells were loaded onto WT or MFG-E8-KO
BMDC for 4 h, and measured the uptake of dying cells as
CD11c
+PKH26
+ populations by flow cytometry. To our surprise,
the ingestion of apoptotic cells was comparable between WT and
MFG-E8 KO DC, indicating that BMDC may utilize compen-
satory machineries for apoptotic cell engulfment using other
mechanisms independent of MFG-E8. In contrast, the engulfment
of necrotic cells was significantly increased in MFG-E8-KO
compared to wild-type DC, but was inhibited by RIP-1 inhibitor
Necrostatin-1 [13] (Figure 2A and B). These results demonstrate
that MFG-E8 deficiency promotes the uptake of necrotic cells in
BMDC.
Figure 1. MFG-E8-deficiecy confers BMDC with an activated phenotype under steady and inflammatory conditions. (A) Five different
sequences of small interfering RNA for MFG-E8 (MFG-E8i #1-#5) or a control gene (control siRNA) were introduced into immature BMDC for 48 h and
the mRNA levels of MFG-E8 were quantified by RT-PCR. The mature DC (mDC) stimulated with CD40 ligand (CD40L) serve as a control due to their low
MFG-E8 expression. (B) The expression levels of CD86 on CD11c
+DC were evaluated by flow cytometry. The percentage (left) and mean fluorescence
intensity (MFI) of CD86 among CD11c+DC was shown as a representative data and statistical analysis (n=3), respectively. (C) The expression levels of
CD83 and MHC-II were evaluated in DC from wild-type (WT) and MFG-E8-decifient (MFG-E8-KO) mice. The representative data (upper) and statistical
analysis of three independent experiments (bottom) are shown. * p,0.05, ** p,0.01, ns: not significant.
doi:10.1371/journal.pone.0039607.g001
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production in DC primed by necrotic cells
We next compared the cytokine profiles of MFG-E8-KO and
wild-type DC loaded with dying cells. Although MFG-E8-KO
iDC had a greater capacity for production of cytokines IFN-b, IL-
1b, IL-6, IL-12, but not IL-10, compared to wild-type iDC when
loaded with necrotic cells, the cytokine profiles were comparable
when wild-type and MFG-E8-KO DC were stimulated with
apoptotic cells (Figure 3A and B). Although the MFG-E8 siRNA
#3 and #4 increased IL-6 and IL-12p40 in BMDC upon
ingestion of either apoptotic or necrotic cells, respectively, these
might be not specific effects by MFG-E8 inhibition because these
siRNA did not efficiently suppress MFG-E8 expression (Figure 1A
and 3A). Moreover, the levels of pro-inflammatory cytokines were
significantly suppressed in MFG-E8-KO DC when primed by
Necrostatin-1-pretreated necrotic cells (Figure 3B). Together, these
results demonstrate that activating necrotic signals facilitate
proinflammatory cytokines production in MFG-E8-KO cell or
cells in which MFG-E8 expression is inhibited by siRNA
compared to MFG-E8-competent DC.
MFG-E8-mediated uptake of necrotic cells regulates
distinct sets of signals that are critical for DC homeostasis
Accumulating evidence has validated the contribution of several
sets of transcription factors to the regulation of tolerogenic DC
activities [14]. In particular, the Stats and NF-kB families have
emerged as critical regulators of DC immunogenic activities
[15,16]. We therefore investigated the role of MFG-E8 in the
regulation of these transcription factors. Knockdown of MFG-E8
with siRNAs or MFG-E8-deficiency diminished phosphorylation
levels of Stat3 in DC primed with necrotic cells, which was
restored by the treatment with Necrostatin-1 (Figure 4A and B).
These findings are in accord with the contribution of Stat3 to the
tolerogenic functions of DC [15,17]. Furthermore, the expression
levels of the deubiquitinase A20 were markedly repressed in MFG-
E8-KO DC primed with necrotic cells, which was reversed by
Necrostatin-1 (Figure 4A and B). These findings were consistent
with previous studies that A20 restricts proinflammatory activities
and maintains the quiescent status of DC under steady and
inflammatory conditions [18]. Moreover, the transcriptional
activities of ISRE and NF-kB were increased in MFG-E8-KO
DC primed with necrotic cells (Figure 4C). Altogether these results
indicate that MFG-E8 plays an important role in the regulation of
signal cascades that are critical in maintaining immune homeo-
stasis of DC.
MFG-E8 inhibition augments antigen-specific responses
by necrotic cell-primed DC
We next evaluated the role of MFG-E8 in the regulation of DC
cross-presentation to CD8
+ T lymphocytes. In this assay, DC were
pulsed with dying tumor cells and used to stimulate purified donor
CD8
+ T cells isolated from OT-I mice, and OVA-specific IFN-c
production in the cocultured cells was assessed by ELISA. OT-I
cells demonstrated robust OVA-dependent responses to cross-
presentation of necrotic B16 tumor cells by wild-type DC. In
contrast, minimal reactivity was induced against apoptotic EG7
cells or irrelevant apoptotic or necrotic tumor cells (B16 and 3LL)
(Figure 5A). Moreover, MFG-E8-deficient DC induced a much
greater potential for Granzyme-B expression and more abundant
OVA-specific CD8
+T cell populations compared to DC obtained
from wild-type mice, as quantified as frequencies of H-2Kb-
restricted OVA tetramer (SIINFEKL)-positive OT-I cells
(Figure 5B).
Programmed necrosis mediates the activation of RIP1/3 kinase
and deubiquitinating enzyme CYLD, which is counteracted by
caspase-8 or FADD (Fas-associated protein with death domain)
[19–22]. Therefore, DC pulsed with necrotic tumor cells were
cocultured with OT-I cells in the presence of Necrostatin-1. The
treatment of necrotic tumor cells with Necrostatin-1 prevented DC
of either wild-type or MFG-E8-KO mice from activating OVA-
specific CTL effector functions (Figure 5C).
These results validate that efficient cross-priming of antigen-
specific T cells by DC is correlated with the extent of necrotic cell
recognition, which is further enhanced by deficiency or pharma-
cological inhibition of MFG-E8.
MFG-E8 is responsible for impeding the antitumor
responses of DC vaccines
Although DC are potent adjuvants for triggering antitumor
immunity, the clinical effects of dendritic cell-based vaccination
remain unsatisfactory [1,23]. To examine whether MFG-E8-
mediated regulation of DC immunogenicity impede antitumor
immunogenicity, we utilized two models for assessing in vivo anti-
tumor responses by DC vaccines.
First, wild-type Balb/c mice were immunized with irradiated
CT26 colon cancer cells, by which CT26-derived antigens were
efficiently recognized by immune cells in the tumor antigen-
irrelevant naı ¨ve mice [24]. The immunized mice were then
injected subcutaneously with a mixture of viable CT26 cells and
BMDC transfected with control or MFG-E8 siRNA-encoded
lentiviral vectors and pulsed with necrotic CT26 cells or not. The
treatment with control or MFG-E8 siRNA-transfected, unpulsed
DC was ineffective to control the established tumors, whereas the
vaccination of MFG-E8 siRNA-transfected DC pulsed with
necrotic CT26 cells induced superior antitumor responses
compared to those of control siRNA-transfected ones (Figure 6A).
As a second model, immature BMDCs generated from wild-
type or MFG-E8 KO mice were loaded with necrotic B16-OVA
(MO-4) or B16 cells, and then used as a vaccine adjuvant against
established B16-OVA tumors. The treatment with wild-type DC
primed with necrotic B16 tumor cells was ineffective against
established tumors. In contrast, the vaccination of MFG-E8-KO
DC loaded with necrotic B16-OVA cells triggered substantial
antitumor effects at greater levels than those of wild-type DC
loaded with necrotic B16-OVA cells (Figure 6B). The vaccination
with the MFG-E8-KO DC did not different from those with the
WT DC on antitumor effects when DC were loaded with
apoptotic B16-OVA cells (data not shown).
These results indicate that pre-immunization or presence of
tumor-specific antigens might be required for breaking tolerance,
Figure 2. MFG-E8-deficient DC exhibit increased uptake of necrotic tumor cells. PKH26-labeled EL4 cells were treated with CDDP or c-
irradiation (IR) (30 Gy) to induce apoptotic cell death, or treated with CDDP and zVAD-fms to induce necrosis. The apoptotic or necrotic cells were
incubated with BMDCs from wild-type (WT) or MFG-E8-deficient (MFG-E8-KO) mice for 2 h. In some instances, necrotic cells were treated with the
RIP1 inhibitor Necrostatin-1 or DMSO for 48 h before co-culture with DC. The uptake of EL4 cells by CD11c
+BMDCs was quantified by flow cytometry.
Representative data (A) and statistical analysis from two experiments (B) are shown. The percentage of PKH26
+CD11c
+ and PKH26
2CD11c
+
populations was shown in right-upper and right-bottom quadrant of each data, respectively. Results are representative of two independent
experiments. * p,0.05, ns: not significant.
doi:10.1371/journal.pone.0039607.g002
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further promote tumor eradication in the in vivo settings.
To analyze the mechanisms underlying these effects, we isolated
tumor tissues derived from B16-OVA from mice with established
tumors after treatment with the DC vaccines primed with necrotic
or apoptotic B16-OVA tumor cells. Vaccination with necrotic cell-
primed MFG-E8-KO DC produced greater frequencies of CD8
+
T cells in tumor-infiltrating lymphocytes isolated from mice than
did necrotic cell-primed WT DC (Figure 6C). Quantification of
tumor-infiltrating CD8
+ T cells expressing Granzyme-B or
binding H-2K
b-OVA tetramer revealed that vaccination with
necrotic cell-primed MFG-E8 KO DC increased the frequency of
OVA-specific CD8
+ cytotoxic T lymphocytes in tumor tissues
(Figure 6D and Figure S2). In contrast, the CTL frequencies and
activities in spleen from MFG-E8-deficient mice were comparable
to those from wild-type mice (data not shown).
Collectively, these findings validate the importance of MFG-E8
in attenuating protective antitumor immunity by fine-tuning the
recognition of signals delivered by necrotic tumor cells.
Discussion
Recent evidence has unveiled the significance of distinct types of
cell death signals in the regulation of immune homeostasis,
developments, and effector activities [5,10,25]. In particular, non-
apoptotic types of cell death, represented by autophagy and
necrosis, have emerged as alternative pathways in the modulation
of inflammation and protective immune responses [12]. In fact,
necrotic cell death mediates inflammation and autoimmunity
through TNFR and RIP1/3-mediated antagonism of apoptotic
pathways [19–22]. However, few mediators that differentially
recognize distinct cell death and are suitable for therapeutic
manipulation have been identified.
We demonstrate in this study that MFG-E8 functions as an
endogenous effector of DC immunogenicity, and attenuates pro-
inflammatory and antitumor immunity through suppression of DC
cross-presentation of necrotic cell-derived antigens. These findings
validate an unexpected function of MFG-E8 in dictating the
immune recognition systems, which may be dependent on distinct
types of cell death signals.
MFG-E8 regulates DC immunogenicity by manipulating
discrete sets of downstream signals that are critical for the
maintenance of immune homeostasis, including Stat-3 and A20.
Previous studies suggested that MFG-E8 activates diverse array of
oncogenic signals such as Stat3, Hedgehog, Akt/PI3K and twist-1,
in tumor cells [7,26]. Although MFG-E8 serves as ligand for
integrin-avb3, it remains largely unknown whether MFG-E8
controls such a broad array of cascades in immune and tumor cells
through integrin-mediated signals. Further studies should identify
downstream adaptors of MFG-E8 that convey oncogenic and
tolerogenic signals by integrin-dependent and –independent
mechanisms.
Figure 3. MFG-E8-deficiency increases proinflammatory cytokine production in DC. (A) BMDC transfected with control or various MFG-E8
siRNAs (#1–#4) were loaded with apoptotic or necrotic cells prepared as described in Figure 2, and the protein levels of IL-1b, IL-6, IL-12p40 and IL-
10 in culture supernatants were measured by ELISA. (B) BMDC from wild-type (WT) or MFG-E8-deficient mice (MFG-E8 KO) were loaded with dying
cells as described above. In some instances, necrotic cells were treated with Necrostatin-1 for 48 h before coculture with BMDC. The protein levels of
IFN-b, IL-6 and IL-12 were determined by ELISA. Results are representative of three independent experiments. * p,0.05, ns: not significant.
doi:10.1371/journal.pone.0039607.g003
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specific responses by modulating apoptotic cell engulfment and
processing [4,9]. We showed that MFG-E8 restrains the cross-
priming of necrotic cell-derived antigens by DC, but cross-
presentation of target antigens via apoptotic cell recognition is
ineffective irrespective of MFG-E8-mediated phagocytosis. Recent
evidence reveals that the death signals related to apoptosis, such as
caspase-8 and FADD, serve as negative regulators of necroptosis
by suppressing RIP3 kinase-dependent signals [27–29]. In this
respect, it is tempting to speculate that MFG-E8-mediated signals
may interact with sentinels of apoptotic death signals, such as
FADD and pro-apoptotic Bcl–2 family members. Alternatively,
the co-factors and adaptors activated by MFG-E8 may interfere
with the TNF-mediated inflammatory signal cascade and RIP
kinase activities in dying tumor cells. In this context, it is also
important to clarify the molecular linkage between necrotic-
associated signals and cross-priming of particular antigens arising
from dying tumor cells.
Recent evidence has clarified that efficient cross-presentation of
immunogenic antigens serves as a key goal to achieve a multiple
array of antitumor immune responses by DC-targeted vaccines
[1,14,30]. Moreover, the activation of innate immune signals
mediated by TLR, NLR and/or CD40 may sense DC to facilitate
cross-presentation of immunogenic tumor antigens and trigger
specific T cell responses [31]. In this regard, the pharmacological
targeting of MFG-E8 in combination with other sets of innate
immune adjuvants may has a profound impact on exploring new
type of DC-based immunotherapy, which may lead to efficient
control of advanced tumors.
In summary, our findings provide novel mechanisms by which
targeting MFG-E8 may generate potent antitumor modalities by
facilitating recognition of immunogenic antigens and suppressing
deleterious processing of dying cells. The coupling of MFG-E8
inhibitors to agents that stimulate necrotic tumor cell death might
be considered a new strategy for improving current anticancer
regimens in clinical settings.
Figure 4. MFG-E8-mediated phagocytosis of necrotic tumor cells modulates distinct sets of signals in DC, which are critical for the
maintenance of immune homeostasis. (A) Immunoblot for A20, pSTAT3 and STAT3 on lysates from BMDC transfected with control or MFG-E8
siRNA 2 h after uptake of apoptotic or necrotic cells. (B) Densitometric analysis of A20 relative to b-actin (mRNA) or p-STAT3-positive populations
relative to total STAT3 (protein) in wild-type (WT) or MFG-E8-deficient (MFG-E8 KO) BMDC primed with apoptotic cells, necrotic cells or necrotic cells
pretreated with Necrostatin-1 was examined by quantitative PCR or western blot, respectively. (C) WT or MFG-E8-KO BMDC were transfected with
firefly luciferase ISRE or NF-kB reporter plasmids for 16 h, and loaded with apoptotic cells (CDDP and IR), necrotic cells (CDDP + zVAD-fms and IR +
zVAD-fms) or LPS for 2 h. Luciferase assays were performed to measure transcriptional activities of ISRE and NF-kB. Data are representative of three
independent experiments. * p,0.05, ns: not significant.
doi:10.1371/journal.pone.0039607.g004
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Mice
C57BL/6 and Balb/c mice were purchased from SCL and
Charles River, respectively. MFG-E8 knockout mice and OT-I
mice were kindly provided by Prof. Shigekazu Nagata (Kyoto
University) and Prof. Shigeo Koyasu (Keio University), respec-
tively. All experiments were conducted under a protocol approved
by the animal care committees of Hokkaido University.
Tumor cells
The tumor cells (CT26 colon carcinoma cells, B16 melanoma
cells, and EG7 thymoma cells) were obtained from the American
Tissue Culture Collection (ATCC). B16 melanoma cells express-
ing OVA genes (B16-OVA: clone MO4) were kindly provided by
Professor Hideo Yagita (Juntendo University) and used as
described previously [8]. All cell lines described above were
obtained one year before experiments were initiated, and
authenticated by the Central Institute for Experimental Animals
(Kawasaki, Japan) for interspecies and mycoplasma contamination
by PCR three months before the experiments.
siRNA construction and transduction
The design, preparation, and transduction of siRNA vectors
were performed as described previously [7]. In brief, expression
plasmids containing murine MFG-E8 siRNA were obtained from
Invitrogen, and transfected into DC according to the manufac-
turer’s instructions. The gene knockdown efficacies were assessed
by RT-PCR and were ranged from 35 to 95% (Figure 1A). The
siRNA sequences specific for murine MFG-E8 were:
59-CCGAGACCAACTACTACAACCTGGA-39 (#1); 59-
CCAACTACTACAACCTGGATGGAGA-39 (#2); 59-
CCTCCAGCAGCTACAAGACATGGAA-30(#3); 59-
CCCACTTGGGAAGGCTGGATAATCA-39 (#4); 59-CA-
CATCCAGTATGTGGCGTCCTACA-39 (#5).
Figure 5. MFG-E8 attenuates cross-priming activities of necrotic cell-derived antigens in DC. (A) WT or MFG-E8-KO BMDC were loaded
with apoptotic or necrotic tumor cells (EG7, B16 or 3LL) for 2 h, and co-cultured with OVA-specific TCR-transgenic CD8
+ T cells for 72 h. IFNc
production in culture supernatants were quantified by ELISA (B) Control or MFG-E8 siRNA-transfected BMDC were loaded with EG7 cells treated with
CDDP (apoptosis) or CDDP and zVAD-fms (Necrosis) for 48 h. Intracellular Granzyme-B (GZM-B) expression or H-2Kb-restricted OVA tetramer
(SIINFEKL)-positive populations in CD8
+ cells were analyzed by flow cytometry. The representative data (left) and statistical analysis of three
independent experiments (right) are shown. (C) WT or MFG-E8-KO BMDC were loaded with the apoptotic (CDDP or IR) or necrotic (CDDP + zVAD-fms
or IR + zVAD-fms) EG7 cells and co-cultured with OVA-specific TCR- transgenic CD8
+ T cells to measure IFNc production by flow cytometry. For some
instances, necrotic EG7 cells were treated with Necrostatin-1 or DMSO for 12 h. Similar results were obtained from three experiments. * p,0.05, ns:
not significant.
doi:10.1371/journal.pone.0039607.g005
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The phenotype of BMDC was analyzed by flow cytometry using
anti-CD11c, anti-CD83, anti-CD86 and anti-MHC-II (BD
Bioscience). For intracellular staining, BMDC were treated with
brefeldin-A (Sigma-Aldrich), stained with anti-CD11c, fixed,
permeabilized with Cytofix/Cytoperm buffer, and stained again
with PE-conjugated Abs for phospho-Stat3 (BD Bioscience). In
some cases, IFN-c, IL-10 and IL-12 were quantified by ELISA
(BD Bioscience) using supernatant obtained from cultured BMDC.
Phagocytosis assay
B16 melanoma cells were treated with CDDP or exposed to c-
irradiation (30 Gy) to trigger apoptosis (more than 80%). Other
cells were treated with CDDP or c-irradiation in the presence of
caspase inhibitor zVAD-fms or subjected to multiple cycles of
freeze-thaw to trigger necrosis. The apoptotic or necrotic cells
were labeled with PKH26 red fluorescent dye (Sigma-Aldrich).
BMDCs were cocultured with the labeled apoptotic or necrotic
cells for 4 h and phagocytosis efficiency evaluated by flow
cytometry.
Figure 6. MFG-E8 inhibition stimulates antitumor adaptive immunity by necrotic cell-pulsed DC. (A) Balb/c mice were immunized with
irradiated CT26 colon cancer cells (1610
6/mice) once a week for three times. The immunized mice (n=5 per each group) were injected
subcutaneously with a mixture of viable CT26 cells and BMDCs transfected with control or MFG-E8 siRNA-encoded lentiviral vectors and pulsed with
necrotic CT26 cells or not (1610
6/mice) on the indicated days (Bold arrows). Tumor growth was measured on the indicated days. (B) WT or MFG-E8-
KO BMDC (n=5 per each group) were loaded with necrotic cells derived from B16 melanoma cells (B16 pulse) or those engineered to express OVA
(B16-OVA) (B16-OVA pulse), and used as vaccines against established B16-OVA tumors in C57Bl/6 mice (n=4 per group) on the indicated day. Tumor
growth was measured on the indicated days (Bold arrows). Non-treatment (NT) groups serve as a control. (C, D) WT or MFG-E8-KO BMDC were loaded
with apoptotic or necrotic cells derived from B16-OVA, and used to challenge C57/Bl6 mice as described above. The CD8
+T cells were isolated and
quantified from tumor tissues 5 days after tumor inoculation, and analyzed for the frequency of total CD8
+T cells (C) or H-2K
b-restricted OVA tetramer
(SIINFEKL)-positive populations (D). Representative dot plots (C) and statistical analysis from two experiments. (C, D) are shown. Results are
representative of at least two independent experiments. * p,0.05, ns: not significant.
doi:10.1371/journal.pone.0039607.g006
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BMDC transfected with control or MFG-E8 siRNA were
subjected to Western blotting using antibodies against phospho-
Stat3, Stat3, A20 (all from Cell Signaling Technology).Beta-actin
was used as a loading control to check the integrity of each sample.
The densitometries of Stat-3, phospho-Stat-3 or A20 were
quantified using image J software.
Transcriptional activities of ISRE and NF-kB
The transcriptional activities of DC were assayed as described
previously [32]. In brief, BMDC were transfected with firefly
luciferase ISRE (Interferon-stimulated response element) or NF-
kB reporter plasmids and 16 h later, loaded with apoptotic or
necrotic cells for 2 h. Luciferase assays were performed to measure
the transcriptional activities of ISRE and NF-kB according to
manufacturer’s instructions (Promega).
In vitro cross-priming assay
BMDCs were co-cultured in 96-well round-bottom plates for
4 h with apoptotic or necrotic B16-OVA or antigen-irrelevant B16
or EL-4 cells (1:10 ratio) that had been labeled with PKH26.
CD11c
+ cells were isolated by magnetic cell sorting (Miltenyi
Biotec), and cocultured with naı ¨ve CD8
+ T cells from the spleens
of OT-I mice for 72 h. Intracellular IFNc or Granzyme-B
expression in T cells was then determined by flow cytometry. In
some experiments, the tumor cells were pretreated with Necros-
tatin-1 (100 mM) before the co-culture to evaluate the contribution
of necrotic cell uptake to the cross-priming of OVA-specific CTLs.
In vivo antitumor effects of DC vaccines
For in vivo tumor experiments, Balb/c mice were immunized
with irradiated CT26 colon cancer cells (1610
6/mouse) once a
week for three times. The immunized mice were injected
subcutaneously with a mixture of viable CT26 cells and BMDCs
transfected with control or MFG-E8 siRNA-encoded lentiviral
vectors and pulsed with necrotic CT26 cells or not (1610
6/mouse)
on day 7 and 14 after tumor inoculation. In additional experi-
ments, C57BL/6 mice were challenged subcutaneously in the
flank with B16 melanoma cells on day 0. For the therapy model,
intratumoral administration of wild-type or MFG-E8-KO DC
(1610
6/mouse) pulsed with necrotic B16 or B16-OVA cells were
performed once a week for two times. Tumor growth was
measured every three days.
Phenotypic analysis of tumor-infiltrating CD8
+ T cells
Tumor infiltrating lymphocytes were obtained from B16-OVA
challenge sites using a Nocoprep (Axis-Shield) cell gradient
separation. The frequencies of CD8
+T cells were analyzed by
flow cytometry using mAb against CD8 and CD3e. The
frequencies of OVA specific CTL were determined by staining
tetramers recognizing H2Db-restricted OVA sequence (SIIN-
FEKL).
Statistics
The differences between two groups were determined with the
Student’s t test or the two-sample t test with Welch’s correction.
The differences among three or more groups were determined
with a one-way ANOVA. The P values less than 0.05 are
considered statistically significant. * p,0.05, ** p,0.01, ns: not
significant.
Supporting Information
Figure S1 Necrostatin-1 suppresses necrotic cell death
mediated by CDDP and zVAD-fms. EL4 thymoma cells were
treated with chemotherapeutic agent cisplatin (CDDP), c-irradi-
ation (IR) with or without pan-caspase inhibitor zVAD-fms to
induce necrosis and apoptosis, respectively. In some instances,
RIP-1 kinase inhibitor Necrostatin-1 was added before CDDP and
zVAD-fms treatment. The necrotic or apoptotic cell death was
shown as annexin-V
2/PI
+ or annexin-V+/PI
+ or – populations,
respectively, by flow cytometry.
(TIF)
Figure S2 In vivo vaccination with MFG-E8-KO DC
enhanced granzyme-B expression in intratumor CTL.
WT or MFG-E8-KO BMDC was loaded with apoptotic or
necrotic cells derived from B16-OVA, and inoculated into B16-
OVA tumors raised from C57/BL6 mice. The cells were isolated
from tumor tissues 5 days after DC treatment, and analyzed for
Granzyme-B expression on CD8
+T cells by intracellular flow
cytometry. Representative data (above) and statistical analysis of
total experiments (n=2) (bottom) is shown.
(TIF)
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